Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index CI

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 437-444

  Staib, Peter ^a   Lathan, Bernd ^a   Schinköthe, Timo ^a   Wiedenmann, Sabine ^a   Pantke, Bernhard ^a   Dimski, Thomas ^a   Voliotis, Dimitris ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Acute myeloid leukemia; Chemosensitivity index Ci; DISC assay; In vitro drug sensitivity; Prognosis

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; CYTARABINE; DANAZOL; DRUG DERIVATIVE; FLAG PROTOCOL; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; TAD PROTOCOL; TAMOXIFEN; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL CRISIS; CELL SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REMISSION; SURVIVAL;

ADULT; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CELL SURVIVAL; CYTARABINE; DANAZOL; DRUG SCREENING ASSAYS, ANTITUMOR; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TAMOXIFEN; VIDARABINE;

EID: 0032611650     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_47     Document Type: Article

References (20)

1. Delmer A, Marie JP, Thevenin D, Cadiou M, Viguie F and Zittoun R. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin One 1989, 7, 738-746.
2. Weisenthal LM, Dill PL, Kurnick NB and Lippman ME. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 1983, 43, 258-264.
3. Weisenthal LM, Marsden JA, Dill PL and Macaluso CK. A novel dye exclusion test for testing in-vitro chemosensitivity of human tumors. Cancer Res 1983, 43, 749-757
4. Kirkpatrick DL, Duke M, Goh TS. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leukemia Res 1990, 14, 459-466.
5. Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G and Veerman AJP. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996, 93, 903-910.
6. Pieters R, Huismans DR, Loonen AH, Hählen K, van der Does-van den Berg A, van Wering ER and Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991, 338, 399-403.
7. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer 1989, 60, 206-210.
8. Bird MC, Godwin VAJ, Antrobus JH, Bosanquet AG. Comparison of in-vitro drug sensitivity by the differential staining cytotoxicity (DISC) assay and colony-forming assays. Br J Cancer 1987, 55, 429-431.
9. Bird MC, Bosanquet AG, Forskitt S, Gilby ED. Semi-micro adaption of a 4-day differential staining cytotoxicity (DISC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res 1986, 10, 445-449.
10. Bosanquet AG. The DISC assay-10 years and 2000 tests further on. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM & Veerman AJP, Eds. Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Studies. Harwood, London. 1993, 373-384.
11. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug sensitivity assay. Lancet 1991, 337, 711-714.
12. Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER and Veerman AJP. In-vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991, 64, 469-474.
13. Bosanquet AG. In-vitro drug sensitivity testing for the individual patient: an ideal adjunct to current methods of treatment choice. Clin Oncol 1993, 5, 195-197.
14. Bosanquet AG. Short-term in-vitro drug sensitivity tests for cancer chemotherapy. A summary of correlations ot test result with both patient response and survival. Forum Trends Exp. Clin. Med. 1994, 4, 179-189.
15. Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. In: Büchner T, Schellong G, Hiddemann W, Ritter J. eds. Haematology and Blood Transfusion. Vol. 33. Acute Leukemias II. Springer Verlag, Berlin, Heidelberg, 1990, 295-298.
16. Staib P., Lathan B., Michel K., Janz E., Schinköthe T. and Diehl V. Predictive value of pretherapeutic in-vitro chemosensitivity testing in adult AML. Haematology and Blood Transfusion 1998, 39, 509-519.
17. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W et al. Intensive consolidation versus prolonged maintenance following intensive induction and conventional consolidation in primary AML: a study by AMLCG. Blood 1996, 88, No 10, Suppl. 1,214a.
18. Wickramanayke PD, Steinmetz HT, Katay I, Glasmacher A, Staib P and Diehl V. Phase II trial of idarubicine, fludarabine, Ara-C and filgrastim (G-CSF) (Ida-FLAG) for the treatment of poor prognosis acut myeloid leukemia (AML). Blood 1995, 86, No 10, suppl. 1, 755a.
19. Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vitro intracellular drug concentrations. Eur J Haematol 1989, 43, 374-384.
20. Veerman AJP and Pieters R. Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 1990, 74, 381-384.